0000899243-23-020714.txt : 20231229
0000899243-23-020714.hdr.sgml : 20231229
20231229203036
ACCESSION NUMBER: 0000899243-23-020714
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231227
FILED AS OF DATE: 20231229
DATE AS OF CHANGE: 20231229
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Young Jonathan
CENTRAL INDEX KEY: 0001779805
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 231529190
MAIL ADDRESS:
STREET 1: C/O AKERO THERAPEUTICS, INC.
STREET 2: 170 HARBOR WAY 3RD FL
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-27
0
0001744659
Akero Therapeutics, Inc.
AKRO
0001779805
Young Jonathan
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Operating Officer
0
Common Stock
2023-12-27
4
M
0
5414
6.36
A
190545
D
Common Stock
2023-12-27
4
S
0
5414
24.00
D
185131
D
Common Stock
20000
I
By EA Irrevocable Trust
Common Stock
20000
I
By CM Irrevocable Trust
Common Stock
20000
I
By JL Irrevocable Trust
Stock Option (Right to Buy)
6.36
2023-12-27
4
M
0
5414
0.00
D
2029-01-15
Common Stock
5414
43064
D
These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
The options are vested and currently exercisable.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $24.0000 to $24.0003, inclusive.
/s/ Jonathan Young
2023-12-29